According to the initial report received, "patient is subject#: (b)(6) in the post-market clinical follow-up study protocol of the on-x ascending aortic prosthesis (aap) retrospective study and was implanted on (b)(6) 2011 with a surgeon made aap device and on-x aortic valve sn#: (b)(6).On (b)(6) 2019 (2941 days post implant) presented to the ed with a complaint of sudden onset of confusion and expressive aphasia.He was admitted for observation and a ct was completed, showing no acute hemorrhage and a small hypoattenuating focus in the left basal ganglia which is new since previous ct but is age-indeterminate.Inr was 2.4 at time of admission.Patient had resolution of symptoms within a few hours and was back to baseline at time of discharge home on (b)(6) 2019.Admitting diagnosis: transient episode of global aphasia.".
|
According to the initial report received, "patient is subject (b)(6) in the post-market clinical follow-up study protocol of the on-x ascending aortic prosthesis (aap) retrospective study and was implanted on (b)(6) 2011 with a surgeon made aap device and on-x aortic valve sn (b)(6).On (b)(6) 2019 (2941 days post implant) presented to the ed with a complaint of sudden onset of confusion and expressive aphasia.He was admitted for observation and a ct was completed, showing no acute hemorrhage and a small hypoattenuating focus in the left basal ganglia which is new since previous ct but is age-indeterminate.Inr was 2.4 at time of admission.Patient had resolution of symptoms within a few hours and was back to baseline at time of discharge home on (b)(6) 2019.Admitting diagnosis : transient episode of global aphasia." this investigation is relegated to onxaap-25, sn (b)(6) (manufacturing date 01nov2009).Receipt of the adjudication form deemed the event not valve related.Per (b)(4) a complaint is ¿written, electronic or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, usability, safety or performance of a medical device that has been released from the organization¿s control or related to a service that affects the performance of such medical devices.¿ based on the information provided to artivion, there is no allegation of deficiency or resultant adverse event cause by the artivion product; therefore, further investigation is not warranted.
|